Logo for Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Investor Relations Material

Latest events

Logo for Eagle Pharmaceuticals Inc

Q2 2023

Eagle Pharmaceuticals
Logo for Eagle Pharmaceuticals

Q3 2023

9 Nov, 2023
Logo for Eagle Pharmaceuticals

Corporate Presentation

27 Sep, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Eagle Pharmaceuticals Inc

Access all reports
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. It primarily offers Ryanodex, an intravenous formulation of dantrolene sodium used for treating patients in various malignant hyperthermia crises. The company also develops Bendeka, a once-daily intravenous formulation of bendamustine hydrochloride that is in late-stage development for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma.